Zhengda Qingjiang's anti-inflammatory drug "celecoxib capsule" passed consistency evaluation
Release date: 2020-01-10 Views: 0
On January 9, China Biopharmaceutical issued an announcement saying that its subsidiary, Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd., has developed a drug registration certificate for the treatment of arthritis, Celecoxib Capsule. This product is the second one of its kind in China to be approved and is deemed to have passed the consistency evaluation.
It is reported that celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor nonsteroidal anti-inflammatory drug, which is used to alleviate the symptoms and signs of osteoarthritis and alleviate the symptoms of human rheumatoid arthritis And signs, treatment of acute pain in adults, etc.
Sales of celecoxib capsules in Chinese public medical institutions (Unit: 10,000 yuan)
According to Minnet.com, the sales of terminal celecoxib capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 1 billion yuan in 2018, a year-on-year increase of 25.28%.
Before that, the manufacturers were Pfizer and Hengrui. China Biopharmaceutical said that the approval of celecoxib capsules will further enrich the Group's product portfolio and help the Group's development in the field of orthopedic medicine.
In terms of consistency evaluation, both Hengrui and Zhengda Qingjiang were approved as imitation 4 types of applications, which are deemed to have passed the consistency evaluation.
Source: Announcement of Listed Company, Minnet Database
- Basic introduction of Heilongjiang Hexiang Pharmaceutical Co., Ltd.
- How to contact Bermuda Medical (Shanghai) Regenerative Medicine Technology Co., Ltd.
- Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Brief introduction of Zaozhuang Yinhai Pharmaceutical Co., Ltd.
- Contact information of Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Introduction of Bermoudi (Shanghai) Regenerative Medicine Technology Co., Ltd.
- 石药集团20个品种过评8个重磅品种获批 1. 20 varieties of CSPC have been approved and 8 heavy varieties have been approved
- 2019年12月药物临床试验报告重点信息 2. Key information of the December 2019 drug clinical trial report
- 一批药停产（附名单） 3. Discontinuation of a batch of drugs (with list)
- 浙江省发布最新医保文件影响所有医院、药企、药店 4. Zhejiang Province issued the latest medical insurance documents affecting all hospitals, pharmaceutical companies, and drug stores
- 施贵宝「阿巴西普注射液」获国家药监局批准上市 5. Bristol-Myers Squibb's `` Abassicept Injection '' was approved by the State Drug Administration for marketing
- 2019年FDA共批准了53个制药公司的108个首仿药 6. In 2019, the FDA approved a total of 108 first generic drugs from 53 pharmaceutical companies
- 恒瑞PD-1正式获批一项临床 7. Hengrui PD-1 was officially approved for a clinical trial